Key result
IL-17 family cytokines drive cardiac fibrosis across cardiovascular diseases with stage-dependent effects.
Why the study?
There is currently no effective treatment for myocardial fibrosis, partly due to its unclear pathogenic mechanism, while IL-17 family cytokines are increasingly shown to be associated with its initiation and propagation.
IL-17 family cytokines are key mediators of myocardial fibrosis across diverse cardiovascular pathologies, highlighting their potential as therapeutic targets for cardiac remodeling.
IL-17 cytokines may represent fibrosis targets in CVD; leaves open the need for stage-specific clinical trials.
Myocardial fibrosis is a common pathological feature in various cardiovascular diseases including myocardial infarction, heart failure, and myocarditis. Generally, persistent myocardial fibrosis correlates with poor prognosis and ranks among the leading causes of death globally. Currently, there is no effective treatment for myocardial fibrosis, partly due to its unclear pathogenic mechanism. Increasing studies have shown IL-17 family cytokines are strongly associated with the initiation and propagation of myocardial fibrosis. This review summarizes the expression, action, and signal transduction mechanisms of IL-17, focusing on its role in fibrosis associated with cardiovascular diseases such as myocardial infarction, heart failure, hypertension, diabetes, and myocarditis. It also discusses its potential as a therapeutic target, offering new insights for the clinical treatment of myocardial fibrosis.
No takes yet. Share an insight, caveat, or question.
Liqing Huang (2024) conducted a review in Cardiac fibrosis. IL-17 family cytokines was evaluated. IL-17 family cytokines play a crucial role in promoting cardiac fibrosis across various cardiovascular diseases, though their specific effects may vary depending on the disease stage and model.